Immunotherapy targets and treatment modalities in AML. The AML cell surface markers, CLEC12A (CLL1), CD33, CD123, and FLT3, can theoretically be used as targets for various immunological modalities, such as antibody-drug conjugates (ADC), T-cell receptor (TCR)–transgenic cytotoxic T lymphocytes (CTL), T-cell recruiting antibody constructs, bispecific T-cell engagers (BiTE), and CAR-T cells. CAR-T cells can be designed using single-targeting CARs or multitargeted CARs, such as dual CARs.